Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 2

Interventions

Sorafenib 26Nivolumab 21pembrolizumab 15Bevacizumab 14lenvatinib 12atezolizumab 9Cyclophosphamide 9Ipilimumab 8durvalumab 6camrelizumab 5apatinib 5Specimen Handling 5Radiosurgery 5tislelizumab 4fludarabine 4Immunotherapy, Adoptive 4Fluorouracil 4Doxorubicin 4tremelimumab 3toripalimab 3sintilimab 3regorafenib 3cabozantinib 3X-Rays 3Magnetic Resonance Spectroscopy 3Injections 3Everolimus 3Ethiodized Oil 3Erlotinib Hydrochloride 3tepotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Hepatocellular × TLC 388 × Clear all
NCT03035006 2018-11-06

Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Taiwan Liposome Company

Phase 1/2 Terminated
1 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01425996 2018-08-21

A Dose-escalation Study of LipotecanĀ® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma

Taiwan Liposome Company

Phase 1/2 Terminated
3 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚔